从8月5日公开信息显示，蓝帆医疗截至2025年7月31日公司股东户数为7.68万户，较上期（2025年7月18日）增加374户， 增幅为0.49%，变化不大。 统计日期股东户数户均持股数（万股）户均持股市值（万元） 2025/07/31768271.318.352025/07/18764531.328.212025/06/20783771.286.872025/03/31810341.246.152025/03/20821571.236.39 来源：金融界 从数据对比来看，蓝帆医疗户均持股数从上期1.32万股下降至本期1.31万股，户均持股市值从上期8.21万元上升至本期 8.35万元。上述区间，蓝帆医疗股价累计下跌1.23%。 截至发稿，蓝帆医疗报6.41元，下跌0.31%，市值64.56亿元。 最新5个统计日期，蓝帆医疗股东户数变动如下： ...

证券之星消息，截至2025年8月4日收盘，蓝帆医疗(002382)报收于6.43元，下跌0.31%，换手率2.09%， 成交量20.88万手，成交额1.32亿元。 8月4日的资金流向数据方面，主力资金净流出805.5万元，占总成交额6.09%，游资资金净流出293.97万 元，占总成交额2.22%，散户资金净流入1099.47万元，占总成交额8.31%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-04 | 6.43 -0.31% | | -805.50万 | -6.09% | -293.97万 | -2.22% | 1099.47万 | 8.31% | | 2025-08-01 | 6.45 | 1.26% | -216.50万 | -1.66% | -515.28万 | -3.94% | 731.78万 | 5.60% | | 2025-07-31 | 6.37 -1.0 ...

Overview - The company, Bluestar Medical Co., Ltd., plans to apply for a total credit limit of up to RMB 1.71 billion for 2025, which includes various types of financing such as working capital loans and bank guarantees [1][3] Credit and Guarantee Situation - The company and its subsidiaries will provide guarantees totaling no more than RMB 1.71 billion, with RMB 1.544 billion allocated for subsidiaries with a debt-to-asset ratio below 70% and RMB 166 million for those at or above 70% [1][3] - The guarantee period is valid for 12 months from the date of the shareholders' meeting resolution [1] Recent Developments - Recently, the company applied for a credit limit of up to RMB 50 million from Zheshang Bank, securing it with a pledge of a RMB 50 million time deposit [3][7] - This guarantee does not exceed the approved limit from the recent board and shareholders' meetings, thus no additional meetings are required for approval [3] Financial Data - As of the announcement date, the total maximum guarantee amount for the company and its subsidiaries is RMB 3,803.58 million, which accounts for 46.46% of the company's audited net assets for 2024 [8] - The company has no overdue guarantees or any litigation related to guarantees [9] Company Information - Bluestar Medical Co., Ltd. was established on December 2, 2002, with a registered capital of RMB 1,007.13 million [4][5] - The company specializes in the production of PVC gloves, nitrile gloves, and various medical devices [5]

7月31日，沪深两融数据显示，蓝帆医疗获融资买入额0.10亿元，居两市第2708位，当日融资偿还额0.18 亿元，净卖出843.38万元。 最近三个交易日，29日-31日，蓝帆医疗分别获融资买入0.13亿元、0.10亿元、0.10亿元。 融券方面，当日融券卖出0.81万股，净卖出0.04万股。 来源：金融界 ...

证券日报网讯7月31日晚间，蓝帆医疗（002382）发布公告称，截至本次担保全部发生后，公司及子公 司的担保最高额为380，357.86万元人民币(外币担保余额均按照2025年7月31日央行公布的汇率折算)， 占公司2024年度经审计净资产的46.46%，未超过2024年度经审计净资产的50%。公司及子公司对合并报 表外单位提供的担保总余额为850万元人民币，占公司2024年度经审计净资产的0.10%。公司及子公司 无逾期对外担保、无涉及诉讼的对外担保及因担保被判决败诉而应承担损失的情形。 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-063 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于公司向银行申请授信提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、担保情况概述 蓝帆医疗股份有限公司（以下简称"公司"）于2024年12月6日召开了第六届董事 会第十六次会议、2024年12月23日召开了2024年第三次临时股东大会，审议并通过了 《关于2025年度公司及子公司申请授信及担保额度预计的议案》，公司及子公司2025 年度拟向银行等金融机构申请综合授信总额不超过人民币17.10亿元，授信品种包括但 不限于流动资金贷款、保函、银行承兑汇票、国内信用证、国内保理、融资租赁等综合 授信业务（具体业务品种以相关金融机构审批为准），具体融资金额将视公司及子公司 生产运营对资金的需求来确定。公司及子公司将根据金融机构的授信要求为上述综合 授信提供担保额度总计不超过人民币17.10亿元，其中，预计为公司及资产负债率70% 以下（ ...

人民财讯7月31日电，蓝帆医疗消息，近日，蓝帆应急科技(武汉)有限公司(简称「蓝帆应急科技」)在武 汉揭牌运营，该公司是蓝帆医疗应急救护事业部为全面开拓国内应急救护市场而设立的业务主体。该事 业部在家用、车载、公共场所、户外、差旅、救灾、宠物等各领域、各场景均有产品布局及市场触达， 已完成绝大部分单品自制及供应链整合，核心产品急救包产能已达2000万套/年。 ...

最近三个交易日，28日-30日，蓝帆医疗分别获融资买入0.18亿元、0.13亿元、0.10亿元。 融券方面，当日融券卖出1.75万股，净卖出0.86万股。 来源：金融界 7月30日，沪深两融数据显示，蓝帆医疗获融资买入额0.10亿元，居两市第2304位，当日融资偿还额0.10 亿元，净买入59.01万元。 ...

Group 1 - The core viewpoint of the article is the establishment of a new company, 蓝帆应急科技(武汉)有限公司, by 蓝帆医疗 to expand its presence in the domestic emergency rescue market [1] - The new company will focus on various fields and scenarios including home, vehicle, public places, outdoor activities, travel, disaster relief, and pet care [1] - The emergency rescue division has completed most of its product manufacturing and supply chain integration, with a core product capacity of 20 million emergency kits per year [1]

Group 1 - The new round of drug procurement rules has been optimized to prevent excessive competition and ensure reasonable price reductions, with the lowest bidding companies required to justify their pricing [1][2] - The optimization of procurement rules reflects a systematic adjustment in high-value consumables procurement policies, moving away from the previous focus on low-price bidding [2] - The first round of coronary stent procurement significantly impacted the performance of winning companies, but the second round introduced a more moderate approach, allowing companies to bid below a set maximum price [2] Group 2 - Bluefan Medical, a leading company in cardiovascular high-value consumables, is expected to achieve better performance in its cardiovascular business due to the "anti-involution" policy changes [3] - The company reported a sales revenue exceeding 690 million yuan for the first half of 2025, representing a growth of over 20% compared to the same period last year, alongside a reduction in sales and management expense ratios [3] - Bluefan Medical has invested a total of 2 billion yuan in research and development from 2018 to 2024, leading to significant product approvals and market growth, including a 120% increase in sales of its innovative drug-coated balloon [4]